Abstract
Induced pluripotent stem cells (iPSCs) hold great promise for the treatment of human diseases, including the failure of bone marrow. Incremental progress across the past three and half decades has brought us closer to making hematopoietic stem cells from iPSCs clinical solutions. A recent innovative two-step differentiation approach successfully generated transplantable HSCs from iPSC sources. For clinical translation, the long-term safety of these gene-altered HSCs must be determined.